Doctor of Medicine, Chief Physician, Associate Professor, Master's Supervisor. Doctor of Medicine, Peking University Health Science Center. Postdoctoral Fellow, Tulane University, USA. Specializes in the diagnosis and treatment of urological tumors, including: prostate cancer, prostate sarcoma, renal cell carcinoma, bladder cancer, renal pelvic and ureteral cancer, adrenal tumors, testicular cancer, penile cancer, urological sarcomas, etc.; Expert in prostate cancer surgery and systemic therapy, bladder preservation strategies and radical cystectomy, as well as surgical and systemic treatment for renal cell carcinoma, renal pelvic and ureteral cancer, and retroperitoneal masses, providing individualized precision treatment plans for urological oncology patients. Concurrent Positions: Youth Committee Member, Urological Oncology Committee, Chinese Anti-Cancer Association; Committee Member, Early Cancer Screening Committee, Beijing Anti-Cancer Association; Vice Chairman and Secretary-General, Urological and Male Reproductive System Professional Committee, Beijing Association for Chronic Disease Prevention and Health Education; Youth Committee Member, Youth Committee, Beijing Urological Association, Beijing Medical Association; Expert, Beijing Medical Association Expert Appraisal Pool; Expert, Beijing Haidian District Medical Association Expert Appraisal Pool; Council Member, Beijing Gonadal Axis Disease Prevention and Treatment Research Association; Committee Member, Chronic Disease Management Group, Urological Oncology Committee, Beijing Oncology Society; Editorial Board Member, *Journal of Urology (Electronic Edition)*; Published 31 SCI and Peking University Core Journal articles as first author and corresponding author. Representative publications: 1. Shuo Wang, Ruijian You, Xiao Yang, et al. The association of HER-2 expression with clinicopathological characteristics and clinical outcomes in patients with localized prostate cancer after radical prostatectomy. *Diagnostics*. 2025, 15. 10.3390/diagnostics15212717. 2. Yudong Cao, Yushuang Cui, Shuo Wang (Co-corresponding author), et al. Comparing the long-term prognosis and renal function changes of partial nephrectomy (PN) and radical nephrectomy (RN) in T1 stage renal cell carcinoma patients. *Transl Androl Urol*. 2025, 14(3): 740-750. 3. Yudong Cao, Jinchao Ma, Shuo Wang (Co-first author), et al. SIRT7 expression predicts poor prognosis in upper tract urothelial carcinoma undergoing postoperative platinum-based adjuvant chemotherapy. *Urol Int*. 2025, 27:1-11. 4. Yudong Cao, Shuo Wang (Co-first author), Jinchao Ma, et al. Mechanistic insights into SIRT7 and EZH2 regulation of cisplatin resistance in bladder cancer cells. *Cell Death Dis*. 2024, 24:15(12):931. 5. Zhao Zhai, Shuo Wang (Co-first author), Yudong Cao, et al. Pan-Cancer analysis reveals the potential of PLOD1 as a prognostic and immune biomarker for human cancer. *2024*, 21:12(12):2653. As Principal Investigator, led 6 provincial/ministerial and institutional projects, and participated in 3 provincial/ministerial projects, totaling 1.5 million RMB. Projects led include: 1. Peking University Cancer Hospital Clinical Research Youth Fund, "An open-label, single-arm, single-center Phase II clinical study evaluating the efficacy and safety of Rezvilutamide combined with androgen deprivation therapy as adjuvant therapy in high-risk patients after radical prostatectomy," October 2025 to December 2029, funding: 200,000 RMB, ongoing, Principal Investigator; 2. Beijing Haidian District Health Development Research Cultivation Plan, No.: HP2024-19-503003, "Correlation study of BRCA gene mutations with tumor characteristics, endocrine therapy sensitivity, and prognosis in metastatic hormone-sensitive prostate cancer," January 2024 to December 2025, funding: 50,000 RMB, ongoing, Principal Investigator; 3. Beijing Hospitals Authority Youth Talent Cultivation, "Qingmiao Plan," No.: QMIL20231114, "Predictive study of CTCs AR-V7 detection on endocrine therapy sensitivity in metastatic hormone-sensitive prostate cancer," January 2023 to December 2024, funding: 70,000 RMB, ongoing, Principal Investigator; 4. Peking University Cancer Hospital Clinical Research Special Fund, Project No.: QNJJ2022004, No.: LGH2023117, "An open-label, single-arm, single-center Phase II clinical study evaluating the efficacy and safety of Disitamab Vedotin (RC48-ADC) in the treatment of metastatic castration-resistant prostate cancer (mCRPC) progressing after novel endocrine therapy," January 2023 to December 2025, funding: 200,000 RMB, ongoing, Principal Investigator; 5. Wu Jieping Foundation Clinical Research Special Fund, No.: 320.6750.2020-19-2, "Correlation study of HRR mutations with endocrine therapy sensitivity and patient prognosis in metastatic hormone-sensitive prostate cancer," August 2021 to December 2022, funding: 50,000 RMB, ongoing, Principal Investigator; 6. Peking University Cancer Hospital Institutional Discipline Backbone Fund, No.: 2021-7, "Study on the role and mechanism of PEP-19 regulating the CaMKKII/AR signaling pathway in prostate cancer," December 2020 to December 2022, funding: 200,000 RMB, completed, Principal Investigator. Served as Deputy Editor-in-Chief and Contributor for 5 books: 1. *Urology*, Contributor; People's Medical Publishing House 2. *Oncologists Talk About Prostate Cancer*, Deputy Editor-in-Chief 3. *Campbell-Walsh Urology Handbook*, Deputy Editor-in-Chief 4. *Doctors Call You for a Checkup*, Contributor; 5. *Journal of Minimally Invasive Treatment of Renal Cell Carcinoma*, Chapter on "Zero-Ischemia Partial Nephrectomy."